Efficacy of the combination of Tenghuangjiangu tablets, alfacalcidol capsules and caltrate D3 tablets in osteoporotic vertebral compression fracture, and their effects on bone metabolic indices

Abstract

Purpose: To investigate the efficacy of the combination of Tenghuangjiangu tablets, Alfacalcidol capsules and Caltrate D3 tablets in osteoporotic vertebral compression fracture (OVCF) and their effects on bone metabolic indices. Methods: Ninety-six patients with OVCF were randomly categorized into study group (SG) and control group (CG). Patients in the CG orally took Caltrate D3 tablets, while those in the SG were given Tenghuangjiangu tablets and Alfacalcidol capsules in addition to caltrate D3 tablets. The Bone mineral density (BMD) values and the treatment efficacy were compared. The levels of bone metabolism markers (PINP, β-CTX, BGP, NBAP), CT and PTH were determined using electrochemiluminescence immunoassay, while Ca2+ levels were assessed using liquid level detection. The incidence of adverse reactions (re-fracture, gastrointestinal reaction, hypotension and abnormal coagulation function) were compared. Results: Treatment efficacy in the SG was 91.67 %, which was significantly higher than that in the CG (81.25 %; p < 0.05). Before treatment, the two groups showed no significant differences in BMD, PINP, β-CTX, BGP, NBAP, Ca2+, CT, and PTH levels (p > 0.05). After treatment, the SG exhibited significantly higher BMD, PINP, BGP, NBAP, Ca2+ and CT levels, and showed lower β-CTX and PTH levels than the CG (p < 0.05). The SG exhibited a significantly lower incidence rate of adverse reactions than that the CG (p < 0.05). Conclusion: The combination of Tenghuangjiangu tablets, Alfacalcidol capsules, and Caltrate D3 tablets, improves bone metabolic indices, bone density and treatment efficacy while reducing the incidence rate of adverse reactions.